IMR Press / FBL / Volume 16 / Issue 2 / DOI: 10.2741/3694

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Molecular imaging metrics to evaluate response to preclinical therapeutic regimens
Show Less
1 Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical enter, Nashville, TN 37232, USA
2 Department of Radiology and Radiological Science, Vanderbilt University Medical Center, Nashville, TN 37232
3 Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232
4 Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232
5 Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN 37232
6 Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232
Front. Biosci. (Landmark Ed) 2011, 16(2), 393–410;
Published: 1 January 2011

Molecular imaging comprises a range of techniques, spanning not only several imaging modalities but also many disease states and organ sites. While advances in new technology platforms have enabled a deeper understanding of the cellular and molecular basis of malignancy, reliable non-invasive imaging metrics remain an important tool for both diagnostics and patient management. Furthermore, the non- invasive nature of molecular imaging can overcome shortcomings associated with traditional biological approaches and provide valuable information relevant to patient care. Integration of information from multiple imaging techniques has the potential to provide a more comprehensive understanding of specific tumor characteristics, tumor status, and treatment response.

Back to top